Claims for Patent: 11,617,713

Summary for Patent: 11,617,713

Title:	Liquid naloxone spray
Abstract:	The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
Inventor(s):	Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
Assignee:	Hikma Pharmaceuticals USA Inc
Application Number:	US17/198,387
Patent Claims:	1. A liquid spray formulation comprising: from about 4% to about 10% w/w naloxone or a pharmaceutically acceptable salt thereof; from about 20% to about 50% w/w ethanol; from about 5% to about 10% w/w propylene glycol; from about 35% to about 71% w/w water; and from about 0.005% to about 0.01% w/w edetate disodium dihydrate, wherein w/w denotes weight by total weight of the formulation. 2. The liquid spray formulation of claim 1, wherein the formulation does not contain an isotonicity agent. 3. The liquid spray formulation of claim 2, wherein the formulation does not contain sodium chloride. 4. The liquid spray formulation of claim 1, where in the formulation does not contain benzalkonium chloride. 5. A method of treating opioid dependence comprising administering the formulation of claim 1 to a patient in need thereof, wherein administration occurs either intranasally, sublingually, or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly. 6. The method of claim 5, wherein administration occurs intranasally. 7. A method of treating opioid overdose comprising administering the formulation of claim 1 to a patient in need thereof, wherein administration occurs either intranasally, sublingually, or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly. 8. The method of claim 7, wherein administration occurs intranasally. 9. A method of treating congenital sensitivity to pain with anhidrosis comprising administering the formulation of claim 1 to a patient in need thereof, wherein administration occurs either intranasally, sublingually, or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly. 10. The method of claim 9, wherein administration occurs intranasally. 11. A liquid spray formulation comprising: about 8.8% w/w naloxone, or a pharmaceutically acceptable salt thereof, about 66% w/w water, about 5.0% w/w propylene glycol and about 20.0% w/w ethanol, and about 0.01% w/w edetate disodium dihydrate, wherein the formulation does not contain an isotonicity agent or a buffer, wherein w/w denotes weight by weight of the total formulation. 12. A method of treating opioid dependence comprising administering the formulation of claim 11 to a patient in need thereof, wherein administration occurs either intranasally, sublingually, or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly. 13. A method of treating opioid overdose comprising administering the formulation of claim 11 to a patient in need thereof, wherein administration occurs either intranasally, sublingually, or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly. 14. A method of treating congenital sensitivity to pain with anhidrosis comprising administering the formulation of claim 12 to a patient in need thereof, wherein administration occurs either intranasally, sublingually, or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly. 15. A liquid spray formulation comprising: about 9.5% w/w naloxone, or a pharmaceutically acceptable salt thereof; about 36% w/w water; about 5.0% w/w propylene glycol; about 50.0% w/w ethanol; and about 0.005% w/w edetate disodium dihydrate, wherein the formulation does not contain an isotonicity agent or a buffer and, wherein w/w denotes weight by weight of the total formulation. 16. A method of treating opioid dependence comprising administering the formulation of claim 15 to a patient in need thereof, wherein administration occurs either intranasally, sublingually, or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly. 17. A method of treating opioid overdose comprising administering the formulation of claim 15 to a patient in need thereof, wherein administration occurs either intranasally, sublingually, or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly. 18. A method of treating congenital sensitivity to pain with anhidrosis comprising administering the formulation of claim 15 to a patient in need thereof, wherein administration occurs either intranasally, sublingually, or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly.